Internal Medicine, Hematology & Oncology · Germantown, TN
NPI
1639170665
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
7945 Wolf River Blvd
Germantown, TN, 38138
Phone (901) 683-0055
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.1M
99,398 services
Medicare patients, 2024
1,226
Average age 74
Drug cost, 2024
$5.8M
4,120 prescriptions
Company payments, 2025
$3,376
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Thomas W Ratliff was code J9271 (injection, pembrolizumab, 1 mg), 12,200 times for 35 patients. In total Thomas W Ratliff billed 99,398 services in 204 codes, and Medicare paid $2.1M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-04-04.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 12,200 | 35 | $44.66 | $545K |
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 11,250 | 15 | $0.86 | $9,684 |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 5,600 | 12 | $0.06 | $313 |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 4,340 | 23 | $2.31 | $10K |
| J0897 Injection, denosumab, 1 mg | Office | 2,760 | 31 | $20.21 | $56K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 2,200 | 21 | $16.38 | $36K |
| J9267 Injection, paclitaxel, 1 mg | Office | 2,192 | 11 | $0.08 | $183 |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2,160 | 11 | $39.08 | $84K |
| 85025 Blood Count | Office | 1,894 | 490 | $7.55 | $14K |
| 80048 Clinical Chemistry | Office | 1,702 | 489 | $8.23 | $14K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,633 | 90 | $0.09 | $149 |
| 80076 Clinical Chemistry | Office | 1,606 | 486 | $7.98 | $13K |
| 99232 Hospital E&M - Subsequent | Facility | 1,433 | 348 | $58.89 | $84K |
| Q5107 Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | Office | 1,410 | 15 | $20.74 | $29K |
| 36415 Venipuncture Blood Collection | Office | 1,353 | 441 | $8.59 | $12K |
By year: 2022 $577K for 22,155 services; 2023 $451K for 17,778 services; 2024 $2.1M for 99,398 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,894 | 490 | $7.55 | $14K |
| 80048 Clinical Chemistry | 1,702 | 489 | $8.23 | $14K |
| 80076 Clinical Chemistry | 1,606 | 486 | $7.98 | $13K |
| 36415 Venipuncture Blood Collection | 1,353 | 441 | $8.59 | $12K |
| 88185 Surgical Pathology Examination | 1,288 | 52 | $17.02 | $22K |
| 82306 Clinical Chemistry | 511 | 330 | $28.77 | $15K |
| 82784 Immunoassay | 443 | 102 | $9.11 | $4,037 |
| 82728 Clinical Chemistry | 406 | 204 | $13.24 | $5,377 |
| 83550 Clinical Chemistry | 342 | 181 | $8.48 | $2,901 |
| 83540 Clinical Chemistry | 342 | 181 | $6.27 | $2,146 |
Medicare prescription drug claims, 2024
In 2024, the drug Thomas W Ratliff prescribed most often to Medicare patients was Potassium Chloride, with 205 prescriptions and refills. In total Thomas W Ratliff wrote 4,120 Medicare prescriptions that cost $5.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Potassium Chloride Generic | 205 | 421 | 79 | $4,226 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 199 | 199 | 58 | $5,176 |
| Eliquis Apixaban | 178 | 311 | 44 | $185K |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 176 | 176 | 41 | $5,504 |
| Oxycodone Hcl Generic | 153 | 153 | 40 | $4,153 |
| Gabapentin Generic | 149 | 185 | 43 | $1,379 |
| Alprazolam Generic | 147 | 147 | 26 | $1,090 |
| Ondansetron Odt Ondansetron | 129 | 130 | 72 | $2,894 |
| Xarelto Rivaroxaban | 103 | 201 | 26 | $106K |
| Anastrozole Generic | 95 | 224 | 28 | $1,671 |
| Vitamin D2 Ergocalciferol (Vitamin D2) | 93 | 151 | 26 | $719 |
| Levothyroxine Sodium Generic | 74 | 191 | 27 | $962 |
| Prochlorperazine Maleate Generic | 67 | 67 | 45 | $1,167 |
| Revlimid Lenalidomide | 66 | 66 | Under 11 | $1.1M |
| Tramadol Hcl Generic | 65 | 65 | 18 | $494 |
Brand drugs: - claims; generic drugs: 3,244 claims; opioid claims: 645.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Thomas W Ratliff $3,376 ($3,376 in general payments such as food, travel and fees) from 21 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $1,696.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 3 | $1,696 |
| Daiichi Sankyo Inc. 4568.T | 4 | $723 |
| Gilead Sciences, Inc. GILD | 6 | $155 |
| BeOne Medicines USA, Inc. ONC | 4 | $147 |
| Astellas Pharma US Inc 4503.T | 2 | $91.29 |
| Abbvie Inc. ABBV | 4 | $77.94 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $71.04 |
| Pfizer Inc. PFE | 3 | $51.88 |
| GlaxoSmithKline, LLC. GSK | 2 | $49.44 |
| Caris MPI, Inc. | 2 | $42.22 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.